Magenta Therapeutics

About Us

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Recent discoveries in stem cell transplant conditioning, mobilization, and expansion have the potential to improve the safety and efficacy of the procedure and allow more patients to obtain treatment. These scientific breakthroughs emerging from Harvard University and Children’s Hospital Boston have made it clear the field is ready for innovation. To translate these discoveries into therapeutics the leading life science venture capital firms, Third Rock Ventures and Atlas Venture have collaborated to create Magenta Therapeutics.

Magenta has several meanings for us:

Bold chimerism: Magenta is a special color that doesn’t exist in normal light. It is created by the combination of red and blue, and is a chimeric color. Chimerism is the hallmark of a successful stem cell transplant when the new and the old immune system exists together. Magenta is a bold color and matches our bold vision in developing and discovering innovative ways to improve stem cell transplant.

Renewal: Hematopoietic stem cells are self-renewing cells that reside in the bone marrow and give rise to the entire blood and immune system. This stem cell is at the core of our work to replace dysfunctional blood and immune systems.

Leadership

Jason Gardner

Jason Gardner

Chief Executive Officer, President and Cofounder
Bastiano Sanna

Bastiano Sanna

Chief Operating Officer
Michael Cooke

Michael Cooke

Chief Scientific Officer
Christina Isacson

Christina Isacson

VP and Head of Business Development

Board of Directors

Mike Bonney

Mike Bonney

Chairman
Jason Gardner

Jason Gardner

Chief Executive Officer, President and Cofounder
Alexis Borisy

Alexis Borisy

Bruce Booth

Bruce Booth

Tom Daniel

Tom Daniel

Scientific Advisory Board

Lead Investors

Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit https://atlasventure.com.

Third Rock Ventures

Third Rock Ventures is the leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people’s lives. By combining our team’s scientific vision, strategic leadership, operational expertise and innovative deal-making capabilities, we nurture bold ideas that translate into successful business enterprises. Recognizing that the best way to create value for our investors is to create value for patients, our companies are built on a solid foundation of science, medicine, people and business strategy. For more information, please visit http://www.thirdrockventures.com.